Servier will present new data in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10–13, 2022 in New Orleans.
The research to be presented includes findings from a real-world analysis comparing overall survival among adolescent and young adults with newly-diagnosed ALL treated with pediatric-inspired regimens versus non-pediatric-inspired regimens.
These latest data add to the growing body of evidence from Servier’s expanding oncology portfolio and underscore its commitment to finding innovative solutions to meet high unmet medical needs.
“Five years after making our strategic commitment to the fight against cancer, the ASH conference allows us to highlight the progress made by the Group, our teams and our partners in developing targeted therapeutic solutions to treat patients with hard-to-treat cancer.”
Claude Bertrand, Executive Vice President Research and Development of the Servier Group